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SURGERY: CAUTION ADVISED
To the Editor:
We recently read the interesting
study by McKellar and associates1
evaluating the effectiveness of dabiga-
tran for thromboprophylaxis after im-
plantation of mechanical heart valves.
Using a heterotopic aortic valvemodel,
the authors randomized 30 swine to
receive dabigatran, enoxaparin, or no
anticoagulation after implantation of
a mechanical valve conduit. At 30
days, McKellar and associates1 re-
ported that dabigatran reduced throm-
bus and platelet deposition on the
mechanical valve leaflets without an
increase in adverse events.
Several new oral direct thrombin in-
hibitors are being evaluated as alterna-
tives for long-term anticoagulation
because of the widely known difficul-
ties associatedwithwarfarin, including
its long half-life and unpredictable
dose response. Compared with warfa-
rin, dabigatran has no food or drug in-
teractions, has a rapid onset of action,
and does not require blood monitor-
ing.2,3 Paradoxically, while lauded for
its ease of use, the management of
patients receiving dabigatran may be
extremely challenging in the setting
of active bleeding and coagulopathy.
McKellar and colleagues1 claim that,
in contrast to warfarin, dabigatran
‘‘could prove safer should emergency
surgery be needed.’’ We respectfully
disagree with this statement. There is
no known antidote available for dabi-
gatran. Vitamin K and fresh frozen
plasma are ineffective, and dialysis
maybe the onlymeans available to rap-
idly reverse the anticoagulant effects of
dabigatran.4,5
We recently prescribed dabigatran
to a 74-year-old woman after coronary1288 The Journal of Thoracic andartery bypass graft surgery. The pa-
tient had a history of atrial fibrillation
and had previously refused warfarin
therapy. After surgery, she continued
to refuse warfarin, but she agreed to
take dabigatran to reduce the risk of
stroke and systemic embolism.6 Dabi-
gatran was initiated on postoperative
day 3 using the lowest possible dose
(75mg twice daily), given the patient’s
frailty and mild renal insufficiency.
She was monitored in the hospital for
6 additional days before transfer to
a rehabilitation facility. A chest x-ray
film before discharge noted a very
small left pleural effusion. Twodays af-
ter transfer, the patient returned to hos-
pital with a massive left hemothorax
and gastrointestinal bleeding. She was
treated with intubation for respiratory
distress and placement of a left thora-
costomy tube, draining more than 2 L
of blood. The patient had evidence of
a severe coagulopathy, with an interna-
tional normalized ratio of 21.5 and
a partial thromboplastin time of 161.2.
Tomanage the bleeding, we instituted
emergency dialysis, successfully cor-
recting the coagulopathy. After 2 di-
alysis treatments, the international
normalized ratio and partial thrombo-
plastin time were reduced to 1.9 and
47.4, respectively, and the chest and
gastrointestinal bleeding had sub-
sided. The patient made a miraculous
recovery and was discharged back to
rehabilitation 2 weeks later without
anticoagulation therapy.
McKellar and associates1 are to be
congratulated for their novel study.
Their animal model data suggest that
dabigatran may have a role in the
thromboprophylaxis of mechanical
valves. Wewould be intrigued to learn
whether they have had any clinical ex-
perience using dabigatran in patients
undergoing cardiac surgery, either
for the thromboprophylaxis of me-
chanical valves or for the anticoagula-
tion of atrial fibrillation. Although our
experience is limited to a single case,
the outcome was nearly fatal. We
would therefore strongly advise cau-
tion when prescribing dabigatranCardiovascular Surgery c November 20early after cardiac surgery, at least un-
til additional clinical experience
accrues.
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ARTERY OR CONUS ARTERY
WITH SEPARATE ORIFICE?
To the Editor:
In their recent Cardiothoracic Im-
aging article, Chen, Chien, and Lee1
have applied the term ‘‘double right
coronary artery’’1 (RCA) in a debat-
able way.
The anatomic nomenclature for the
situation they have described has
been better termed ‘‘the conus artery:
a third coronary artery’’2; ‘‘conus cor-
onary artery with aortic origin’’3; or,
more appropriately, ‘‘conus artery
with separate orifice,’’ coded as11
